Endogenous von Hippel-Lindau tumor suppressor protein regulates catecholaminergic phenotype in PC12 cells

Cancer Research

Volumn 62, Issue 6, 2002, Pages 1682-1687

  Bauer, Amy L ^a   Paulding, Waltke R ^a   Striet, Justin B ^a   Schnell, Phillip O ^a   Czyzyk Krzeska, Maria F ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; DNA FRAGMENT; HYPOXIA INDUCIBLE FACTOR 1; TRANSCRIPTION FACTOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ARTICLE; CATECHOLAMINE SYNTHESIS; CELL STRAIN; CONTROLLED STUDY; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HYPERTENSION; HYPOXIA; NONHUMAN; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

ANIMALS; CATECHOLAMINES; CELL HYPOXIA; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; LIGASES; LYMPHOKINES; PC12 CELLS; RATS; RNA, ANTISENSE; RNA, MESSENGER; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; TYROSINE 3-MONOOXYGENASE; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0037086279     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Von Hippel-Lindau disease
2. Identification of the von Hippel-Lindau disease tumor suppressor gene
3. Tumor suppression by the human von Hippel-Lindau gene product
4. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein
5. Activation of HIF1α ubiquitination by a reconstituted von Hippellindau (VHL) tumor suppressor complex
6. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein
7. 2 sensing
8. 2-regulated prolyl hydroxylation
9. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas
10. Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease
11. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein
12. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing clongins B/C and Cul2
13. Diagnosis and management of pheochromocytoma
14. Pheochromocytoma as the first manifestation of von Hippel-Lindau disease
15. Molecular genetic diagnosis of von Hippel-Lindau disease in familial pheochromocytoma
16. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas
17. Pheochromocytoma in von Hippel-Lindau disease: Clinical presentation and mutation analysis in a large multigenerational kindred
18. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes
19. The relationship between enzyme activity and the catecholamine content and secretion of pheochromocytomas
20. Expression of mRNA coding for four catecholamine-synthesizing enzymes in human adrenal pheochromocytoma
21. Regulation of catecholamine synthesizing enzyme gene expression in human pheochromocytoma
22. Von Hippel Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells
23. 2-responsive sequences on the tyrosine hydroxylase gene
24. Role of c-fos in hypoxia-induced AP-1 cis-element activity and tyrosine hydroxylase gene expression
25. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum levels in evaluation of patients with adrenal tumors
26. Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumors
27. Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene
28. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene
29. The von Hippel-Lindau tumor suppressor gene product interacts with Spl to repress vascular endothelial growth factor promoter activity
30. Tissue-specific transcription of the rat tyrosine hydroxylase gene requires synergy between an AP-1 motif and an overlapping E box-containing dyad
31. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor-1
32. Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells